Cargando…
Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients
Infiltration of malignant cells into the central nervous system in hematological malignancies correlates with poor clinical outcomes. Investigations into the penetration of venetoclax into the central nervous system have been limited. We report venetoclax pharmacokinetics in plasma and cerebrospinal...
Autores principales: | Badawi, Mohamed, Menon, Rajeev, Place, Andrew E., Palenski, Tammy, Sunkersett, Gauri, Arrendale, Richard, Deng, Rong, Federico, Sara M., Cooper, Todd M., Salem, Ahmed Hamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197937/ https://www.ncbi.nlm.nih.gov/pubmed/37215448 http://dx.doi.org/10.7150/jca.81795 |
Ejemplares similares
-
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
por: Badawi, Mohamed, et al.
Publicado: (2022) -
Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023) -
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Brackman, Deanna, et al.
Publicado: (2022) -
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
por: Samineni, Divya, et al.
Publicado: (2022) -
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies
por: Gopalakrishnan, Sathej, et al.
Publicado: (2023)